| Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why |
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-05-05 13:51:17 |
Czytaj oryginał (ang.) |
| Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year? |
Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year. |
zacks.com |
2025-05-02 14:46:05 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade |
The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-04-25 14:55:36 |
Czytaj oryginał (ang.) |
| What Makes Benitec Biopharma (BNTC) a New Buy Stock |
Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-04-23 17:00:42 |
Czytaj oryginał (ang.) |
| Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer |
We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing function, with significant commercial opportunities and an undervalued stock price reflecting high-dose cohort data. Financially, Benitec has no revenue, rising operating expenses, and a cash balance of $78.3 million, providing a runway into mid-2027, though burn rate may increase. |
seekingalpha.com |
2025-04-16 03:51:31 |
Czytaj oryginał (ang.) |
| Insiders Are Loving These 5 Tech and Biotech Stocks |
After struggling through a rough patch, the biotech industry seems to be staging a comeback. |
247wallst.com |
2025-04-02 12:45:46 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering |
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-20 12:55:31 |
Czytaj oryginał (ang.) |
| Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable |
Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2025-02-20 11:50:38 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update |
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. |
globenewswire.com |
2025-02-14 10:10:00 |
Czytaj oryginał (ang.) |
| Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock |
Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2025-01-13 12:51:15 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why |
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-12-25 11:51:17 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High? |
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-12-09 12:56:15 |
Czytaj oryginał (ang.) |
| Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why |
Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-12-09 11:50:24 |
Czytaj oryginał (ang.) |
| Benitec Biopharma to Participate in Upcoming Investor Conferences in December |
HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences. |
globenewswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update |
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society- |
globenewswire.com |
2024-11-14 18:30:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference |
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. |
globenewswire.com |
2024-11-04 10:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma: OPMD Program Continues To Advance With Catalysts |
Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing. |
seekingalpha.com |
2024-10-17 19:35:10 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Announces Updated Investor Webcast Information |
-Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- |
globenewswire.com |
2024-10-14 10:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society |
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- |
globenewswire.com |
2024-10-12 10:30:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update |
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July- |
globenewswire.com |
2024-09-26 20:30:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society |
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czech Republic from October 8-12, 2024. The Late Breaking Abstract entitled “Interim Clinical Data Summary: A Phase 1b/2a Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of an AAV9-based gene therapy (BB-301) Administered to Subjects with Oculopharyngeal Muscular Dystrophy (OPMD) with Dysphagia” will be presented on October 12, 2024. |
globenewswire.com |
2024-09-18 12:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study |
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study- |
globenewswire.com |
2024-07-15 10:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update |
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- |
globenewswire.com |
2024-05-13 12:15:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study |
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- |
globenewswire.com |
2024-04-18 11:30:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million |
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2,584,239 shares of its common stock at a price per pre-funded warrant of $4.7999, to certain institutional accredited investors. The oversubscribed financing was led by Suvretta Capital Management, LLC (“Suvretta Capital”) with participation from new and existing investors including Adage Capital Partners L.P., Nantahala Capital, multiple healthcare-focused funds, and a leading mutual fund. Gross proceeds from the PIPE financing total approximately $40.0 million, before deducting offering expenses. The closing price of the Company's common stock on April 17, 2024 was $4.80. |
globenewswire.com |
2024-04-18 11:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update |
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject Scheduled to Receive BB-301 in February 2024- -23 Subjects Enrolled into the Oculopharyngeal Muscular Dystrophy Natural History Study with Multiple Subjects Eligible for entry into the Phase 1b/2a Clinical Treatment Study in 2024- HAYWARD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its second fiscal quarter ended December 31, 2023. |
globenewswire.com |
2024-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy |
Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec's “Silence and Replace” DNA-directed RNA interference gene therapy platform Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec's “Silence and Replace” DNA-directed RNA interference gene therapy platform |
globenewswire.com |
2023-11-30 09:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference |
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday, November 30th, 2023 at 10:00 am ET. |
globenewswire.com |
2023-11-17 10:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update |
HAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its First Fiscal Quarter ended September 30, 2023. |
globenewswire.com |
2023-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update |
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia |
globenewswire.com |
2023-09-21 12:00:00 |
Czytaj oryginał (ang.) |